The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes

Amy K. Saenger, Allan S Jaffe

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The advent of inexpensive, highly accurate, and predictive markers of myocardial injury, inflammation, and hemodynamic stability has revolutionized the evaluation and treatment of patients who have acute coronary syndromes (ACSs). These blood biomarkers require small sample volumes, can be run expeditiously, and provide important information concerning the diagnosis, risk stratification, and treatment of these patients. To understand the use of these markers, one must have some knowledge about what elevations in these markers imply, how they have to be collected and measured to provide reliable information, when to suspect analytic confounds, and what the key values are that impart the diagnostic, prognostic, and therapeutic information. This article discusses these issues, emphasizing what clinicians must know for optimal test use, and then addresses the practical use of these markers in patients who have ACS.

Original languageEnglish (US)
Pages (from-to)657-681
Number of pages25
JournalMedical Clinics of North America
Volume91
Issue number4
DOIs
StatePublished - Jul 2007

Fingerprint

Acute Coronary Syndrome
Biomarkers
Therapeutics
Hemodynamics
Inflammation
Wounds and Injuries

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes. / Saenger, Amy K.; Jaffe, Allan S.

In: Medical Clinics of North America, Vol. 91, No. 4, 07.2007, p. 657-681.

Research output: Contribution to journalArticle

@article{d8af572bdca04fddb852681c5414a550,
title = "The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes",
abstract = "The advent of inexpensive, highly accurate, and predictive markers of myocardial injury, inflammation, and hemodynamic stability has revolutionized the evaluation and treatment of patients who have acute coronary syndromes (ACSs). These blood biomarkers require small sample volumes, can be run expeditiously, and provide important information concerning the diagnosis, risk stratification, and treatment of these patients. To understand the use of these markers, one must have some knowledge about what elevations in these markers imply, how they have to be collected and measured to provide reliable information, when to suspect analytic confounds, and what the key values are that impart the diagnostic, prognostic, and therapeutic information. This article discusses these issues, emphasizing what clinicians must know for optimal test use, and then addresses the practical use of these markers in patients who have ACS.",
author = "Saenger, {Amy K.} and Jaffe, {Allan S}",
year = "2007",
month = "7",
doi = "10.1016/j.mcna.2007.04.001",
language = "English (US)",
volume = "91",
pages = "657--681",
journal = "Medical Clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - The Use of Biomarkers for the Evaluation and Treatment of Patients with Acute Coronary Syndromes

AU - Saenger, Amy K.

AU - Jaffe, Allan S

PY - 2007/7

Y1 - 2007/7

N2 - The advent of inexpensive, highly accurate, and predictive markers of myocardial injury, inflammation, and hemodynamic stability has revolutionized the evaluation and treatment of patients who have acute coronary syndromes (ACSs). These blood biomarkers require small sample volumes, can be run expeditiously, and provide important information concerning the diagnosis, risk stratification, and treatment of these patients. To understand the use of these markers, one must have some knowledge about what elevations in these markers imply, how they have to be collected and measured to provide reliable information, when to suspect analytic confounds, and what the key values are that impart the diagnostic, prognostic, and therapeutic information. This article discusses these issues, emphasizing what clinicians must know for optimal test use, and then addresses the practical use of these markers in patients who have ACS.

AB - The advent of inexpensive, highly accurate, and predictive markers of myocardial injury, inflammation, and hemodynamic stability has revolutionized the evaluation and treatment of patients who have acute coronary syndromes (ACSs). These blood biomarkers require small sample volumes, can be run expeditiously, and provide important information concerning the diagnosis, risk stratification, and treatment of these patients. To understand the use of these markers, one must have some knowledge about what elevations in these markers imply, how they have to be collected and measured to provide reliable information, when to suspect analytic confounds, and what the key values are that impart the diagnostic, prognostic, and therapeutic information. This article discusses these issues, emphasizing what clinicians must know for optimal test use, and then addresses the practical use of these markers in patients who have ACS.

UR - http://www.scopus.com/inward/record.url?scp=34447299702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447299702&partnerID=8YFLogxK

U2 - 10.1016/j.mcna.2007.04.001

DO - 10.1016/j.mcna.2007.04.001

M3 - Article

VL - 91

SP - 657

EP - 681

JO - Medical Clinics of North America

JF - Medical Clinics of North America

SN - 0025-7125

IS - 4

ER -